Sg3 Management, LLC Intellia Therapeutics, Inc. Call Options Transaction History

Sg3 Management, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	SELL	$33.3 - $44.82 $166,500 - $224,100	-5,000 Closed	0 $0
Q3 2022 May 15, 2023	BUY	$53.92 - $71.7 $269,600 - $358,500	5,000 New	5,000 $279,000
Q3 2022 Nov 14, 2022	SELL	$53.92 - $71.7 $846,544 - $1.13 Million	-15,700 Reduced 75.85%	5,000 $280,000
Q2 2022 Aug 15, 2022	BUY	$38.49 - $76.21 $508,068 - $1.01 Million	13,200 Added 176.0%	20,700 $1.07 Million
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $437,025 - $892,425	7,500 New	7,500 $545,000
Q4 2021 Feb 15, 2022	SELL	$100.76 - $138.36 $201,520 - $276,720	-2,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$132.37 - $176.78 $5.03 Million - $6.72 Million	-38,000 Reduced 95.0%	2,000 $268,000
Q2 2021 Aug 16, 2021	BUY	$60.88 - $161.91 $2.01 Million - $5.34 Million	33,000 Added 471.43%	40,000 $6.48 Million
Q1 2021 May 17, 2021	BUY	$46.59 - $83.68 $326,130 - $585,760	7,000 New	7,000 $562,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $775M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.